menu
    • menu

    Company profile for Cabaletta Bio

    NEW Drugs in Dev: 4
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that are designed to precisely ablate specific autoantibody-producing B cells while sparing normal antibody-producing B cells that protect the body from infection. C...
    Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that are designed to precisely ablate specific autoantibody-producing B cells while sparing normal antibody-producing B cells that protect the body from infection. CAAR T cells are based on the revolutionary chimeric antigen receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cabaletta BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    150 N Radnor Chester Rd Suite F-200 Radnor, PA 19087
    Telephone
    Telephone
    +1 610 977 2422
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cabalettabio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cabalettabio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cabaletta Bio, Cellares Ink 10-Year Supply Deal For Rese-Cel
    Cabaletta Bio, Cellares Ink 10-Year Supply Deal For Rese-Cel

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282575/0/en/cabaletta-bio-and-cellares-announce-10-year-commercial-supply-agreement-for-rese-cel.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Cabaletta Bio Doses First Patients with Rese-cel from Cellares
    Cabaletta Bio Doses First Patients with Rese-cel from Cellares

    14 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-14/first-patients-dosed-with-cabaletta-bio-s-rese-cel-manufactured-on-cellares-automated-cell-shuttle

    PHARMIWEB
    14 Apr 2026
    Share Share
    Cabaletta Bio Reports 2025 Financials And Business Update
    Cabaletta Bio Reports 2025 Financials And Business Update

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260280/0/en/Cabaletta-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Cabaletta Bio Joins TD Cowen Health Care Conference
    Cabaletta Bio Joins TD Cowen Health Care Conference

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243502/0/en/Cabaletta-Bio-to-Participate-in-the-TD-Cowen-46th-Annual-Health-Care-Conference.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Cabaletta Bio Joins Guggenheim Biotech Summit 2026
    Cabaletta Bio Joins Guggenheim Biotech Summit 2026

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232923/0/en/Cabaletta-Bio-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Cabaletta Bio Clears IND Amendment For Rese-Cel Manufacturing
    Cabaletta Bio Clears IND Amendment For Rese-Cel Manufacturing

    12 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-12/ind-amendment-clearance-obtained-for-clinical-manufacturing-of-rese-cel-from-cabaletta-bio-using-cel

    PHARMIWEB
    12 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search